Table 5.
Summary of putative clinical impact of APP treatment involving partial agonists.
Issue | Type | Putative clinical impact (target/s) |
---|---|---|
Positive symptoms | Desired | Improvement (partial D2) |
Negative symptoms | Desired | Improvement (partial D3) |
Hyperprolactinaemia (RIS, HAL, PAL) | AE | Attenuation (partial D2) |
Weight/metabolic (e.g., OLA, CLZ) | AE | Improvement (interaction partial D2 vs. H1/5-HT2C?) |
Sedation (e.g., OLA, RIS) | AE | Improvement (interaction partial D2 vs. H1?) |